Direct-to-Patient (DTP) logistics and decentralized clinical trials (DCT) are no longer a thing of the future. They are in use today, they are staying, and they’ve brought advances in study timeline efficiencies, patient retention, and supplies management technologies that we never thought possible.
The swift evolution of technology and the increasing remote capabilities of study management over the last few years, have removed pre-existing roadblocks that previously had no viable resolution in sight. Join Cat Hall, Endpoint’s Vice-President Data and Quality as she explains the roadblocks of the past, the improvement the industry has made, and what can be expected today and in the future.
In this article you will discover:
- New implications to consider when increasing direct-to-patient interactions
- Challenges at the forefront today with DTP and decentralized trials
- The role and evolution of technology in advancing trial design and the way clinical trials are conducted
Fill out this form to download the article